Join to View Full Profile
200 Medical 530 420 120 Plz# 365Los Angeles, CA 90095
Phone+1 310-794-9718
Fax+1 310-301-8751
Dr. Kelley is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2006 - 2009
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2002 - 2005
David Geffen School of Medicine at UCLAClass of 2002
Certifications & Licensure
CA State Medical License 2003 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
Clinical Trials
- Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2009 Nov 17
- A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Start of enrollment: 2016 May 19
Publications & Presentations
PubMed
- A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.Pasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, Leonardo Brunetti, Giulia Francesca Manfredi
Journal of Hepatology. 2026-06-15 - Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.Josep M Llovet, Ezequiel Mauro, Lorenza Rimassa, Vincenzo Mazzaferro, Matthias Pinter
Nature Reviews. Clinical Oncology. 2026-06-10 - Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fàbrega
Journal of Hepatology. 2026-06-01
Lectures
- Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC...2019 ASCO Annual Meeting - 6/1/2019
- Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Atezolizumab plus Bevacizumab — A Landmark in Liver CancerMay 2020
Press Mentions
American Association for Cancer Research, April 14-19May 8th, 2023- Fears Rise That UC Strike Could Have Long-Lasting Consequences on Vaunted Research, TeachingNovember 28th, 2022
- Priming Tremelimumab Dose Regimen Shows Promising Benefit-Risk Profile in HCCOctober 19th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
